Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 4/20 | 0.66 |
| ▸ | SOS2 | Q07890 | 1/20 | 0.66 |
| ▸ | NCF1 | P14598 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 6/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30044428 | 1.00 | NR4A2 (0.66) | NR4A2SOS2NCF1HTTKDM4E | |
| SCHEMBL30210360 | 0.83 | NR4A2 (0.66) | NR4A2SOS2NCF1HTTKDM4E | |
| SCHEMBL4823097 | 0.83 | NR4A2 (0.66) | NR4A2SOS2NCF1HTTKDM4E | |
| Bromide SCHEMBL5989384 | 0.81 | NR4A2 (0.63) | NR4A2SOS2NCF1HTTKDM4E | |
| SCHEMBL3063873 | 0.79 | CCR1 (0.48) | NR4A2SOS2HTTKDM4EALDH1A1 | |
| SCHEMBL624006 | 0.79 | NR4A2 (0.61) | NR4A2SOS2NCF1ALDH1A1ACHE | |
| SCHEMBL3319590 | 0.79 | NR4A2 (0.61) | NR4A2SOS2NCF1HTTHSP90AA1 | |
| SCHEMBL31452673 | 0.79 | NR4A2 (0.61) | NR4A2SOS2NCF1KDM4EALDH1A1 | |
| SCHEMBL31285386 | 0.79 | NR4A2 (0.61) | NR4A2SOS2NCF1HTTEGFR | |
| SCHEMBL596040 | 0.79 | NR4A2 (1.00) | NR4A2SOS2NCF1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105530938-B | Compounds for the treatment of diseases caused by retroviruses | ABIVAX公司 | 2019-10-22 | — | — | CN | claimed |
| CN-104945379-B | Compounds for the treatment of premature aging and especially premature aging | ABIVAX公司 | 2018-11-30 | — | — | CN | claimed |
| CN-1259942-A | Novel guanidine mimics as factor Xa inhibitors | DU PONT MERCK PHARMA (US) | 2000-07-12 | — | — | CN | claimed |
| US-20240199613-A1 | POLYCYCLIC INHIBITORS OF PLASMA KALLIKREIN | TAKEDA PHARMACEUTICALS CO (JP) | 2024-06-20 | — | — | US | disclosed |
| CN-116354879-A | Benzamide derivative and application thereof | 中国药科大学 | 2023-06-30 | — | — | CN | disclosed |
| CN-106928194-B | Compounds for the treatment of premature aging and especially premature aging | ABIVAX公司 | 2019-11-12 | — | — | CN | disclosed |
| CN-105530938-B | Compounds for the treatment of diseases caused by retroviruses | ABIVAX公司 | 2019-10-22 | — | — | CN | disclosed |
| CN-106905232-B | Compounds for the treatment of premature aging and especially premature aging | ABIVAX公司 | 2019-09-27 | — | — | CN | disclosed |
| CN-106928205-B | Compounds for the treatment of premature aging and especially premature aging | ABIVAX公司 | 2019-09-24 | — | — | CN | disclosed |
| CN-109776496-A | Compounds for the treatment of premature aging and especially premature aging | ABIVAX公司 | 2019-05-21 | — | — | CN | disclosed |
| CN-104844510-B | Compounds for the treatment of premature aging and especially premature aging | ABIVAX公司 | 2019-04-23 | — | — | CN | disclosed |
| CN-104844570-B | Compounds for the treatment of premature aging and especially premature aging | ABIVAX公司 | 2018-11-02 | — | — | CN | disclosed |
| CN-106928205-A | Compounds for the treatment of premature aging and especially premature aging | ABIVAX公司 | 2017-07-07 | — | — | CN | disclosed |
| CN-106928194-A | Compounds for the treatment of premature aging and especially premature aging | ABIVAX公司 | 2017-07-07 | — | — | CN | disclosed |
| CN-106905232-A | Compounds for the treatment of premature aging and especially premature aging | ABIVAX公司 | 2017-06-30 | — | — | CN | disclosed |
| US-8399447-B2 | Metal triangulo compound and methods of using the same | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2013-03-19 | — | — | US | disclosed |
| US-20100209431-A1 | METAL TRIANGULO COMPOUND AND METHODS OF USING THE SAME | NATIONAL UNIVERSITY OF SINGAPORE | 2010-08-19 | — | — | US | disclosed |
| EP-2147005-A1 | METAL TRIANGULO COMPOUND AND METHODS OF USING THE SAME | National University of Singapore (SG) | 2010-01-27 | — | — | EP | disclosed |
| WO-2008127197-A1 | METAL TRIANGULO COMPOUND AND METHODS OF USING THE SAME | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2008-10-23 | — | — | WO | disclosed |
| CN-1259942-A | Novel guanidine mimics as factor Xa inhibitors | DU PONT MERCK PHARMA (US) | 2000-07-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100209431-A1 | METAL TRIANGULO COMPOUND AND METHODS OF USING THE SAME | CASP3, BAX, CASP7 | NR4A2 2191/4885SOS2 3361/4885NCF1 494/4885 |
| US-20240199613-A1 | POLYCYCLIC INHIBITORS OF PLASMA KALLIKREIN | KLKB1, KLK1, KLK5 | NR4A2 4008/4885SOS2 4485/4885NCF1 1511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.